Leiomyosarcoma Therapeutics - Pipeline Assessment

and Market Forecasts to 2019

On 19thDecember 2014

Summary
The industry analysis specialist, has released its new report, Leiomyosarcoma Therapeutics Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of
information and analysis on the global Leiomyosarcoma Therapeutics market. The report
identifies the key trends shaping and driving the global Leiomyosarcoma Therapeutics market.
The report also provides insights on the prevalent competitive landscape and the emerging
players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the
global Leiomyosarcoma Therapeutics sector. This report is built using data and information
sourced from proprietary databases, primary and secondary research and in-house analysis by
GlobalDatas team of industry experts.

You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-leiomyosarcoma-therapeutics-pipeline-assessment-and-marketforecasts-135241

Scope
The report provides information on the key drivers and challenges of the Leiomyosarcoma
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan)
Leiomyosarcoma Therapeutics market revenues data from 2006 to 2011, forecast for eight
years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
- Analysis of the current and future competition in the seven key countries Leiomyosarcoma
Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Leiomyosarcoma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Leiomyosarcoma Therapeutics
market

Reasons to buy
The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Leiomyosarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global Leiomyosarcoma Therapeutics
market in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

partnerships.
- Whats the next big thing in the global Leiomyosarcoma Therapeutics market landscape?
Identify, understand and capitalize.

Other industries we cover:

Advertising and Media

Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis

Discounts on Market Research Reports till 31st December, 2014

For more inquiries, contact at +91 - 998 729 5242 /
contact@jsbmarketresearch.com

Table of Content
2 Leiomyosarcoma Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.4 Symptoms
2.5 Diagnosis
2.5.1 Imaging of the affected area and likely areas to be affected
2.5.2 Procedures
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

2.5.3 Laboratory studies

2.6 Staging of Leiomyosarcoma
2.7 Treatment
2.7.1 Surgery
2.7.2 Radiation Therapy
2.7.3 Chemotherapy
2.8 GlobalData Pipeline Report Guidance
3 Leiomyosarcoma Therapeutics - Market Characterization
3.1 Leiomyosarcoma Therapeutics Major Markets, Market Size (2006-2011) - Global
3.2 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Global
3.3 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The US
3.4 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The US
3.5 Leiomyosarcoma Therapeutics Market Size (2006-2011) - The UK
3.6 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - The UK
3.7 Leiomyosarcoma Therapeutics Market Size (2006-2011) - France
3.8 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - France
3.9 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Germany
3.10 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Germany
3.11 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Italy
3.12 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Italy
3.13 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Spain
3.14 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Spain
3.15 Leiomyosarcoma Therapeutics Market Size (2006-2011) - Japan
3.16 Leiomyosarcoma Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Leiomyosarcoma Therapeutics Market
3.17.1 Drivers for the Leiomyosarcoma Therapeutics Market
3.17.2 Barriers for the Leiomyosarcoma Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Leiomyosarcoma Therapeutics - Competitor Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Key Takeaway
5 Leiomyosarcoma Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Leiomyosarcoma Therapeutics - Pre-registration Pipeline
5.2.2 Leiomyosarcoma Therapeutics - Phase III Pipeline
5.2.3 Leiomyosarcoma Therapeutics - Phase II Pipeline
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

5.2.4 Leiomyosarcoma Therapeutics - Phase I Pipeline

5.3 Leiomyosarcoma Therapeutics - Clinical Pipeline by Mechanism of Action
5.3.1 Leiomyosarcoma Therapeutics - Other Mechanisms of Action
5.4 Leiomyosarcoma Technology Trends Analytical Framework
5.5 Leiomyosarcoma Therapeutics - Promising Drugs under Clinical Development
5.6 Profiles of Key Late Stage Drugs under Clinical Development
5.6.1 Ridaforolimus
5.6.2 TH-302
5.6.3 Votrient (pazopanib)
5.6.4 Yondelis (trabectedin)
5.6.5 Halaven (eribulin mesylate)
5.7 Key takeaway
6 Leiomyosarcoma Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Phase
6.2 Clinical Trials by Trial Status
6.3 Clinical Trials by Overall Sponsors
6.4 Clinical Trials by Prominent Sponsors
6.5 Top Companies Participating in Therapeutics Clinical Trials
7 Leiomyosarcoma Therapeutics - Strategic Assessment
7.1 Implications for Future Market Competition
8 Leiomyosarcoma Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Ariad Pharmaceuticals
8.2.2 Merck & Co. Inc.
8.2.3 Johnson & Johnson Pharmaceutical Research & Development, L.L.C
8.2.4 PharmaMar S.A.
8.2.5 Threshold Pharmaceuticals
8.2.6 GlaxoSmithKline
8.2.7 Eisai Co., Ltd.
8.3 Other Companies in the Leiomyosarcoma Market, 2011
8.3.1 Leiomyosarcoma Therapeutics - Other Future Players
9 Leiomyosarcoma Therapeutics - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

9.3.4 Primary Research

9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

List Of Tables
Table 1: Types of Leiomyosarcomas
Table 2: American Joint Committee on Cancer (AJCC) Staging System
Table 3: Musculoskeletal Tumor Society (MSTS) Staging System
Table 4: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 6: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 8: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 9: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 10: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011
Table 11: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019
Table 12: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 13: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 14: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 15: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 16: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 17: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 18: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 20: Leiomyosarcoma Therapeutics - Pre-registration Pipeline, 2011
Table 21: Leiomyosarcoma Therapeutics - Phase III Pipeline, 2011
Table 22: Leiomyosarcoma Therapeutics - Phase II Pipeline, 2011
Table 23: Leiomyosarcoma Therapeutics - Phase I, 2011
Table 24: Leiomyosarcoma Therapeutics, Other Mechanisms of Action from Figure
Table 25: Leiomyosarcoma Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 26: Patient Characteristics in SUCCEED Trial
Table 27: PFS Observed in SUCCEED Trial
Table 28: Adverse Events Observed During SUCCEED Trial
Table 29: Adverse Events Observed with the Class of mTOR Inhibitors
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 30: Responses Shown by Soft Tissue Sarcoma Group in TH-302 Phase II Study
Table 31: Adverse Events of TH-302
Table 32: Hematologic Toxicity Shown by TH-302
Table 33: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011
Table 34: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Phase, 2011
Table 35: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Status, 2011
Table 36: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Overall Sponsors, 2011
Table 37: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Prominent Sponsors, 2011
Table 38: Leiomyosarcoma Therapeutics, Top Companies Participating in Clinical Trials, 2011
Table 39: Ariad Pharmaceuticals, Leiomyosarcoma Pipeline Product, 2011
Table 40: Merck & Co., Leiomyosarcoma Pipeline Product, 2011
Table 41: Threshold Pharmaceuticals Inc., Leiomyosarcoma Pipeline Product, 2011
Table 42: GlaxoSmithKline, Leiomyosarcoma Pipeline Product, 2011
Table 43: Eisai Co., Ltd., Leiomyosarcoma Pipeline Product, 2011

List Of Figures
Figure 1: Leiomyosarcomas at Different Locations in the Body
Figure 2: Treatment Algorithm for Leiomyosarcoma
Figure 3: Leiomyosarcoma Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 4: Leiomyosarcoma Therapeutics Major Market Share , 2011
Figure 5: Leiomyosarcoma Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 6: Leiomyosarcoma Therapeutics Major Market Share ($m), 2019
Figure 7: Leiomyosarcoma Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 8: Leiomyosarcoma Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 9: Leiomyosarcoma Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 10: Leiomyosarcoma Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 11: Leiomyosarcoma Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 12: Leiomyosarcoma Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 13: Leiomyosarcoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 14: Leiomyosarcoma Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 15: Leiomyosarcoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 16: Leiomyosarcoma Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 17: Leiomyosarcoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 18: Leiomyosarcoma Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 19: Leiomyosarcoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 20: Leiomyosarcoma Therapeutics Market, Japan, Forecast ($m), 2011-2019
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 21: Drivers and Barriers for Leiomyosarcoma Therapeutics, 2011

Figure 22: Opportunity and Unmet Need in the Leiomyosarcoma Therapeutics Market, 2011
Figure 23: Leiomyosarcoma Therapeutics, Strategic Competitor Assessment, 2011
Figure 24: Leiomyosarcoma Therapeutics - Pipeline by Phase of Development, 2011
Figure 25: Leiomyosarcoma Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 26: Technology Trends Analytical Framework of the Leiomyosarcoma Pipeline, 2011
Figure 27: Technology Trends Analytical Framework of Leiomyosarcoma Pipeline - Description,
2011
Figure 28: Leiomyosarcoma Therapeutics, Number of Clinical Trials by Country, 2011
Figure 29: Leiomyosarcoma Therapeutics, Clinical Trials by Phase (%), 2011
Figure 30: Leiomyosarcoma Therapeutics, Clinical Trials by Status (%), 2011
Figure 31: Leiomyosarcoma Therapeutics, Clinical Trials by Overall Sponsors (%), 2011
Figure 32: Leiomyosarcoma Therapeutics, Clinical Trials by Prominent Sponsors (%), 2011
Figure 33: Leiomyosarcoma Therapeutics, Companies Participating in Therapeutic Clinical Trials,
2011
Figure 34: Implications for Future Market Competition in Leiomyosarcoma Therapeutic Market,
2011
Figure 35: Leiomyosarcoma Therapeutics, Number of Pipeline Molecules by Company, 2011
Figure 36: GlobalData Market Forecasting Model

Report Price:
Licence Type

Price

PDF

$ 3995

Site Licence

$ 7990

Enterprise Wide Licence

$ 11985

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Related Reports:
Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018
Portal Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Hepatic Encephalopathy - Pipeline Assessment and Market Forecasts to 2019
Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to
2019
Gauchers Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Sarcoidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Pompe Disease (GAA Deficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and
Market Forecasts to 2019
Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com

About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

To know more on Leiomyosarcoma Therapeutics - Pipeline Assessment and

Market Forecasts to 2019
http://www.jsbmarketresearch.com/healthcare-medical/r-leiomyosarcomatherapeutics-pipeline-assessment-and-market-forecasts-135241

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/